Cannabix Technologies Makes Advances with Marijuana Breathalyzer Development and Renews Research with Yost Group
May 29 2019 - 8:35AM
InvestorsHub NewsWire
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Makes
Advances with Marijuana
Breathalyzer Development and
Renews
Research with Yost Group
The Cannabix Marijuana Breathalyzer
system
is being developed to give law enforcement and employers a tool to
enforce public safety.
Vancouver, British
Columbia -- May 29, 2019 -- InvestorsHub NewsWire -- Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or
Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the workplace, is pleased to report that Company
engineers have made a significant breakthrough with the ionization
module which is a vital component of the breathalyzer device, where
breath samples are ionized prior to entrance into the FAIMS cell.
New ion focussing techniques have resulted in a 30% increase in ion
current and transmission/signal strength in testing, further
increasing instrument sensitivity. The Company also reports that it
has been steadily progressing with human breath testing at its
Vancouver, BC, based lab with its FAIMS (field asymmetric waveform
ion mobility spectrometry) ?9-tetrahydrocannabinol (“THC”)
detection device and breath collection unit (“BCU”). Testing and
refinement of the BCU over the last 30 days has led to upgrades in
flow and CO2 sensor components as well as refinements in breath
analysis from various users. Furthermore, engineers are developing
an improved detector component for the system and a smaller
footprint for the ionization chamber. These upgrades are being made
in preparation for a design freeze of the prototype and multi
device creation for additional testing. The Company is also
preparing new marketing materials of its device for potential pilot
users.
The Company is
also pleased to report that it has renewed its ongoing research
engagement with the Dr. Rick Yost group at the University of
Florida (UF). Research at UF is done in parallel with Cannabix
research team in Canada and Gainesville to advance complex
development of breath testing devices using ion mobility. The Yost
Research Group is a world leader and pioneer in the development of
FAIMS, and Cannabix and the Yost Research Group are working
together to identify THC in ultra low ranges using highly sensitive
FAIMS and FAIMS-mass spectrometer
systems.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects previous usage from days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be
hazardous.
We seek
Safe Harbor.
On behalf of the
Board of Directors
“Rav
Mlait”
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this
release.
Cautionary
Statement Regarding Forward-Looking
Statements
This press
release contains forward-looking information that involves various
risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking
statements.
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Sep 2023 to Sep 2024